Kura Oncology

Company snapshot

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline c

• 1 approved product(s) across US/EU regulatory metadata.
• 25 active pipeline program(s) linked via ClinicalTrials.gov.
• 132 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Kura Oncology. Not investment advice.

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

• Peer + 0 momentum

  Eikon Therapeutics

  TA overlap score 23

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for Kura Oncology.

1. Jun 8, 2026 Clinical update

   KO-MEN-017 — Phase 3

2. Jun 8, 2026 Clinical update

   KO-MEN-008 — Phase 1

3. Jun 8, 2026 Clinical update

   Ziftomenib, Ziftomenib — Phase 2

4. Jun 8, 2026 Clinical update

   Ziftomenib — Phase 1

5. Jun 8, 2026 Clinical update

   ziftomenib — Phase 1

View all clinical trial activity →

• What is Kura Oncology?

  Kura Oncology is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker KURA. Primary therapeutic focus areas include Acute Myeloid Leukemia, Relapsed and/or refractory Acute Myeloid Leukemia, Advanced Malignant Neoplasm, NPM1-m and KMT2A-r Acute My

• Is Kura Oncology publicly traded?

  Yes. Kura Oncology is listed with ticker KURA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Kura Oncology develop or market?

  We link 14 drug profile(s) where Kura Oncology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kura-oncology#company-drugs.

• What are the latest developments for Kura Oncology?

  In the last 12 months our linked public records show 25 trial program update(s) and 4 US patent grant(s) tied to this profile.

• What therapeutic areas does Kura Oncology focus on?

  Kura Oncology focuses on Acute Myeloid Leukemia, Relapsed and/or refractory Acute Myeloid Leukemia, Advanced Malignant Neoplasm based on our analysis of their pipeline programs and drug development activities.